- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07912385
Observational Study of the LambdaGuide System for Measurement of Observable Genitourinary Anatomy During Cystoscopic Procedures in Men
This prospective clinical study will evaluate the feasibility, performance, and safety of the LambdaGuide System for obtaining point-to-point measurements of observable genitourinary anatomy during cystoscopic procedures in adult men. The system is intended to provide measurements of anatomical structures visible during cystoscopy without influencing clinical diagnosis or treatment decisions.
The study will assess successful calibration, spatial capture, measurement point selection, and completion of point-to-point measurements. Device usability, procedural workflow effects, and adverse events will also be evaluated. Optional comparisons with known-dimension references may be performed for descriptive purposes.
LambdaGuide measurements will not be used to guide or modify clinical care.
Study Overview
Status
Conditions
Detailed Description
This is a prospective, observational clinical study designed to evaluate the feasibility, functional performance, usability, and safety of the LambdaGuide System during cystoscopic procedures in adult male participants aged 22 years and older.
The LambdaGuide System is an investigational optical measurement system that integrates with a compatible cystoscope. It uses an optical camera module, calibration process, spatial capture, and software-based point selection to obtain point-to-point measurements of anatomical structures visible within the urinary tract.
Participants may include men undergoing non-emergency cystoscopic procedures and, where specifically authorized under the approved research protocol, healthy adult male volunteers. Study participation involves use of the LambdaGuide System during cystoscopic visualization. For patients undergoing clinically indicated cystoscopy, the investigational measurements are performed alongside standard clinical care. LambdaGuide measurements will not be used to make diagnostic or therapeutic decisions, select treatment, or modify standard clinical care.
During the procedure, qualified clinicians will set up the LambdaGuide System, perform calibration using an approved calibration target, and attempt measurements of observable urinary anatomy. Potential measurement targets include anatomical openings or narrowing, urethral strictures, distances between anatomical landmarks, urinary tract lesions, stones, foreign bodies, and implant-related structures.
For each measurement attempt, the study will document the ability to obtain spatial information, select two valid measurement points, and display a point-to-point measurement. The primary performance endpoint is procedure-level clinical measurement feasibility, defined as obtaining at least one successful point-to-point measurement during an evaluable procedure.
Additional assessments include calibration success, camera deployment and image display, spatial capture success, measurement completion, calibration and measurement time, procedural interference, and clinician-reported usability. Optional observational comparisons with known-dimension references may be performed. These comparisons are descriptive and are not intended to establish measurement accuracy.
Safety will be evaluated through documentation of adverse events, including their severity, seriousness, and relationship to the investigational device or study procedures. Device deficiencies and malfunctions will also be recorded. Participants will undergo post-procedure safety assessment and follow-up approximately 30 days after the procedure, within a permitted window of ±5 days.
The study is intended to characterize the LambdaGuide System's ability to obtain measurements of visible genitourinary anatomy in a clinical environment and to collect performance, usability, and safety data to support further device evaluation.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Sarah Lapp
- Phone Number: 678-231-0685
- Email: sarah@lambdasurgical.com
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Recruiting
- PINE (Prostate Institution of New England)
-
Contact:
- Alethia Chan
- Phone Number: 857-800-2305
- Email: chanalethia@gmail.com
-
Principal Investigator:
- Louis Liou, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
No additional description beyond Eligibility Criteria. Subjects should be able to travel to a study site.
Description
Inclusion Criteria:
- Adult male subject (22 years of age or older).
- Subject who undergoes a non-emergency cystoscopic procedure, or a healthy volunteer.
- Able and willing to provide informed consent before study participation.
- Procedure is expected to provide visualization of observable urinary anatomy suitable for an attempted measurement.
- Investigator determines that study participation is appropriate and will not interfere with standard clinical care.
- Investigator determines, based on medical history and physical examination, that the subject is medically appropriate to undergo the study procedures.
Exclusion Criteria:
- Participation is expected to interfere with or materially delay standard clinical care.
- Known clinical condition or procedural circumstance that, in the investigator's judgment, makes study participation inappropriate.
- Inability to provide informed consent.
- Inability to use the required compatible cystoscope or approved study configuration.
- Known allergy or contraindication to the local anesthetic planned for the cystoscopic procedure.
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_ONLY
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical measurement feasibility
Time Frame: Procedure duration
|
Clinical measurement feasibility, assessed as a procedure-level pass/fail outcome. An evaluable procedure passes if at least one successful point-to-point measurement is obtained. |
Procedure duration
|
|
Primary safety endpoint
Time Frame: From procedure date to 30 days after (+/-5 days)
|
Incidence, severity, seriousness, and relatedness of device-related, procedure-related, and other adverse events. |
From procedure date to 30 days after (+/-5 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Calibration success
Time Frame: During Procedure
|
Calibration success |
During Procedure
|
|
Camera deployment and expected image display
Time Frame: During Procedure
|
Camera deployment and expected image display |
During Procedure
|
|
Spatial capture success
Time Frame: During Procedure
|
Spatial capture success |
During Procedure
|
|
Valid point-selection success
Time Frame: During Procedure
|
Valid point-selection success |
During Procedure
|
|
Successful measurement completion
Time Frame: During Procedure
|
Successful measurement completion |
During Procedure
|
|
Calibration and measurement time
Time Frame: During Procedure
|
Calibration and measurement time (descriptive only) |
During Procedure
|
|
Procedure interference
Time Frame: During Procedure
|
Procedure interference |
During Procedure
|
|
User acceptance
Time Frame: During Procedure
|
User acceptance - based on Investigator Questionnaire |
During Procedure
|
|
Observational comparative measurements (
Time Frame: During Procedure
|
Observational comparative measurements (descriptive only) |
During Procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Louis Liou, MD, PhD, PINE - Prostate Institution of New England
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LG-GU-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.